(UNC Lineberger Comprehensive Cancer Center) In JCI Insight, UNC Lineberger's Stergios Moschos, MD, and colleagues published the results of a phase I, multi-institution clinical trial for an investigational treatment for melanoma and other cancers with mutations in the BRAF or RAS genes.
(Mayo Clinic) When people are suffering from a chronic medical condition, they may place their hope on treatments in clinical trials that show early positive results. However, these results may be grossly exaggerated in more than 1 in 3 early clinical trials, reports a new study led by Mayo Clinic and published today in Mayo Clinic Proceedings.
(Scripps Research Institute) 'These results lay the groundwork for the next steps toward FDA approval,' says John Griffin, PhD, professor at TSRI, whose team invented 3K3A-APC.
Stem Cell Treatment Benefits Three-fourths of MS Patients in Phase 1 Trial This is encouraging news for MS patients hoping to see some action in the stem cell area. A Phase 1 mesenchymal stem cell trial is reporting positive results, and a Phase 2 trial is underway in New York. Show More Summary
(Burness) Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents. Show More Summary
Ben Goldacre (previously) led a team that created the FDAAA Trials Tracker, "A live informatics tool to monitor compliance with FDA requirements to report clinical trial results." (more…)
A study from the National Bureau of Economic Research reports on the results of a large randomized controlled trial of a large employer with over 12,000 employees. Program eligibility and financial incentives were randomized at the individual level. Over 56 percent of eligible treatment group employees participated. The study found that in the first year, the employees […]
A stem cell treatment improved the neurological symptoms of three-fourths of the multiple sclerosis patients in a Phase 1 clinical trial, New York researchers reported. The results prompted the team at the Tisch MS Research Center of New York to start a Phase 2 trial to further assess the therapy’s safety and effectiveness. Show More Summary
(American Society for Radiation Oncology) Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine (RAI). Show More Summary
Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the human papillomavirus (HPV), including those with advanced nodal disease, can receive substantially lower radiation doses safely and effectively if they respond to induction chemotherapy initially.
Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine (RAI). Show More Summary
Deep-brain stimulation, a non-invasive way of targeting neurons in the cortex, can significantly ease symptoms of fatigue in multiple sclerosis (MS) patients, research drawn from a clinical trial suggests. These results, published in...Show More Summary
Few research efforts have focused on interventions for adults, but a new six-year collaborative trial tested two treatments for adults with autism -- and found strong, but different, results.
Multiple sclerosis (MS) patients who experience a relapse after two courses of Lemtrada (alemtuzumab) treatment showed improvements in relapse rate and disability after a third Lemtrada course, according to results of the CARE-MS II trial extension. Show More Summary
D.C. Superior Court emailed more than 2,300 District residents alerting them of jury duty, much later than normal.
Celgene’s Ozanimod reduces relapsing multiple sclerosis patients’ relapses, brain lesions, and brain volume loss, a Phase 3 clinical trial shows. The company presented the results of the SUNBEAM trial at the ACTRIMS Forum 2018 convention in San Diego, Feb. Show More Summary
(Brigham and Women's Hospital) Study finds nearly half of all prostate cancer randomized clinical trials use lab results that are more likely to exclude black patients due to racial variations in laboratory values.
MedDay Pharma’s MD1003 leads to long-lasting improvements in progressive multiple sclerosis patients’ disability, a Phase 3 clinical trial follow-up study shows. Researchers presented the results at the third Annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in San Diego, Feb. Show More Summary
(US Army Medical Research Institute of Infectious Diseases) Officials from Bavarian Nordic yesterday announced the results of a successful Phase 3 clinical trial led by USAMRIID that demonstrated the safety and efficacy of the company's investigational, non-replicating smallpox vaccine, IMVAMUNE®. Show More Summary
Researchers Identify Testosterone-triggered Molecule That Protects Men From MS This finding is an extension of research that has already indicated that a higher testosterone level reduces the chance of a person developing multiple sclerosis (MS). Show More Summary